EUCTR2007-001425-10-NL进行中（未招募）不适用
A Study of INT-747 (6-ECDCA) in Combination with Ursodeoxycholic Acid (URSO®, UDCA) in Patients with Primary Biliary Cirrhosis
Intercept Pharmaceuticals0 个研究点目标入组 140 人开始时间: 2008年9月3日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 140
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients are required to meet the following criteria in order to be included in the study:
- •Male or female age 18 to 70 years.
- •Stable dose of ursodeoxycholic acid (URSO®, UDCA) for at least 6 months prior to screening.
- •Female patients must be postmenopausal, surgically sterile, or if premenopausal, prepared to use 1 effective method of contraception with all sexual partners during the study and for 14 days after the end of dosing. Effective methods of contraception are considered to be:
- •o Barrier method, i.e., (a) condom (male or female) or (b) diaphragm with spermicide; or
- •o Hormonal (e.g., contraceptive pill, patch); or
- •o Intrauterine device (IUD); or
- •o Vasectomy (partner).
- •Male patients must be prepared to use 1 effective method of contraception with all sexual partners during the study unless they have had a prior vasectomy.
- •Proven or likely PBC, as demonstrated by the patient presenting with at least 2 of the following 3 diagnostic factors:
- •o History of increased AP levels for at least 6 months prior to Day 0
- •o Positive AMA titer (>1:40 titer on immunofluorescence or M2 positive by ELISA) or PBC-specific antinuclear antibodies (antinuclear dot and nuclear rim positive)
- •o Liver biopsy consistent with PBC
- •Screening AP level between 1.5 and 10 × ULN.
- •Willing and able to give written informed consent
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patients with the following characteristics will be excluded from the study:
- •Administration of the following drugs at any time during the 3 months prior to screening for the study: colchicine, methotrexate, azathioprine, or systemic corticosteroids.
- •Screening conjugated (direct) bilirubin >2 × ULN.
- •Screening ALT or AST >5 × ULN.
- •Screening serum creatinine >1.5 mg/dL (133 ?mol/L).
- •History or presence of hepatic decompensation (e.g., variceal bleeds, encephalopathy, or poorly controlled ascites).
- •History or presence of other concomitant liver diseases including hepatitis due to hepatitis B or C virus (HCV, HBV) infection, primary sclerosing cholangitis (PSC), alcoholic liver disease, definite autoimmune liver disease or biopsy proven nonalcoholic steatohepatitis (NASH).
- •Known history of human immunodeficiency virus (HIV) infection.
- •History or presence of any other disease or condition known to interfere with the absorption, distribution, metabolism, or excretion of drugs including bile salt metabolism in the large intestine (e.g., inflammatory bowel disease).
- •Other clinically significant medical conditions, including renal insufficiency.
- •Other medical conditions that are not well controlled or for which medication needs are anticipated to change during the study. Concomitant medications must be stable for 14 days prior to the first dose of study medication, and should be expected to remain stable during the course of the study.
- •History of alcohol abuse (defined as consumption of more than 210 mL of alcohol per week; or the equivalent of 14 4-ounce glasses of wine, or 14 12-ounce cans/bottles of beer or wine coolers) or other substance abuse within the prior 1 year.
- •Participation in another investigational drug, biologic, or medical device study within 30 days prior to Day 0.
- •History of noncompliance with medical regimens, or patients who are considered to be potentially unreliable.
- •Blood or plasma donation within 30 days prior to dosing.
- •Mental instability or incompetence, such that the validity of informed consent or compliance with the study is uncertain.
- •If female: pregnant, lactating, or positive serum or urine pregnancy test.
研究者
相似试验
进行中（未招募）
不适用
A Study of INT-747 (6-ECDCA) in Combination with Ursodeoxycholic Acid (URSO®, UDCA) in Patients with Primary Biliary CirrhosisEUCTR2007-001425-10-GBIntercept Pharmaceuticals140
已完成
2 期
A Study of INT-747 (6-ECDCA) in Combination with Ursodeoxycholic Acid (URSO®, UDCA) in Patients with Primary Biliary CirrhosisPrimary Billiary Cirrhosis10019654NL-OMON33908Intercept Pharmaceuticals30
进行中（未招募）
1 期
A Study of INT-747 (6-ECDCA) in Combination with Ursodeoxycholic Acid (URSO®, UDCA) in Patients with Primary Biliary CirrhosisPrimary biliary cirrhosisMedDRA version: 9.1Level: PTClassification code 10004661Term: Biliary cirrhosis primaryEUCTR2007-001425-10-FRIntercept Pharmaceuticals140
进行中（未招募）
不适用
A Study of INT-747 (6-ECDCA) in Combination with Ursodeoxycholic Acid (URSO®, UDCA) in Patients with Primary Biliary CirrhosisPrimary biliary cirrhosisMedDRA version: 9.1Level: PTClassification code 10004661Term: Biliary cirrhosis primaryEUCTR2007-001425-10-DEIntercept Pharmaceuticals140
进行中（未招募）
不适用
A Study of INT-747 (6-ECDCA) in Combination with Ursodeoxycholic Acid (URSO®, UDCA) in Patients with Primary Biliary CirrhosisEUCTR2007-001425-10-ATIntercept Pharmaceuticals140